January 24, 2013 Thursday - updated 09:59 AM PT

MissionIR News - Seeking Alpha Publishes Article Featuring VistaGen Therapeutics

Atlanta, United States (IBwire.com - January 24, 2013) MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCQB: VSTA). VistaGen Therapeutics is a biotechnology company applying stem cell technology for drug rescue applications, including predictive toxicology and drug metabolism screening. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate novel, safer, proprietary chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns.

Seeking Alpha recently published the following article featuring VistaGen Therapeutics: http://seekingalpha.com/article/1120881

The article titled “Supreme Court Decision Is Bullish For Stem Cell Companies” reviews the recent high court decision that allows medical universities and science foundations to receive federal funding for embryonic stem cell research. Now supported by the federal government, the stem cell industry is anticipated to be a $6.6 billion market by 2016, more than 50% greater than its present size.

Peter Harengel, author of the article, provided an overview of the progress taking place in the industry as companies continue to move forward with their stem cell research. VistaGen Therapeutics, for instance, recently announced a significant advance in its development of LiverSafe 3D™, a human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism before animal or human testing. As with its CardioSafe 3D™ product, this bioassay system was designed to be used with modern medicinal chemistry to generate safer, proprietary chemical variants ("drug rescue variants") of once-promising drug candidates, as well as identify product failures earlier in the cost curve.

Companies active in stem cell research are now much more attractive for a variety of factors. The election in Washington, D.C. has brought clarity to the health care sector, overall. The major players know what to expect and can now move forward. The recent Supreme Court decision will now focus the attention of many on stem cell research as more federal funding will enter the sector. Also of significance is that the political uncertainty is gone regarding stem cell research.

2013 is poised to introduce a new flood of excitement in this up-and-coming health care market.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Media Contact:

Senior Editor
3645 Marketplace Blvd.
Atlanta, GA

Phone: 404-941-8975
Email: editor@missionir.com
Website: www.missionir.com
creat you account

Terms of Service | Privacy Policy | Link to IBwire | Contact Us

Issuers of press releases and not IBwire are only accountable for the precision of the information they included.
If you have any inquiries or questions concerning the press release please contact the company directly listed in the press release.

© Copyright 2016, IBwire inc

submit press release | press release distribution | press release service